Bisoprolol

• Hypertension
• Heart Failure
• Cardiovascular Protection
• Atrial Fibrillation Rate Control

Bisoprolol is a highly selective beta-1 adrenergic receptor blocker used primarily in the treatment of hypertension and heart failure. This cardioselective beta-blocker provides effective cardiovascular protection with a favorable side effect profile due to its selectivity for cardiac beta-1 receptors.

Mechanism of Action

Bisoprolol competitively blocks beta-1 adrenergic receptors located primarily in the heart. This blockade reduces the effects of catecholamines (epinephrine and norepinephrine) on the heart, resulting in decreased heart rate (negative chronotropic effect), reduced myocardial contractility (negative inotropic effect), slowed atrioventricular conduction (negative dromotropic effect), and decreased renin release. These combined effects lead to reduced cardiac workload, myocardial oxygen consumption, and blood pressure. Bisoprolol has the highest beta-1 selectivity among commonly used beta-blockers, minimizing effects on beta-2 receptors in the lungs and blood vessels.

Available Formulations

Bisoprolol is available as oral tablets in 5 mg and 10 mg strengths. The tablets can be taken with or without food. Generic formulations are widely available. In some countries, combination products with hydrochlorothiazide are available.

Medical Uses

Bisoprolol is FDA-approved for the management of hypertension, alone or in combination with other antihypertensive agents. It is also approved in Europe and widely used for the treatment of stable chronic heart failure with reduced ejection fraction (HFrEF). The CIBIS-II trial demonstrated a significant reduction in all-cause mortality and hospitalizations in heart failure patients treated with bisoprolol. Off-label uses include rate control in atrial fibrillation and prevention of cardiovascular events.

Dosing Guidelines

For hypertension, the initial dose is typically 5 mg once daily. If the antihypertensive effect is inadequate, the dose may be increased to 10 mg and then to a maximum of 20 mg once daily. For heart failure, treatment starts at 1.25 mg once daily and is gradually uptitrated over several weeks to the target dose of 10 mg once daily as tolerated. Dose adjustments are required for hepatic impairment (maximum 10 mg daily) and renal impairment (CrCl less than 40 mL/min: initial dose 2.5 mg, maximum 10 mg daily).

Important Safety Information

Beta-blockers should not be withdrawn abruptly, especially in patients with coronary artery disease, due to the risk of exacerbating angina, myocardial infarction, or ventricular arrhythmias. Bisoprolol is contraindicated in patients with cardiogenic shock, overt cardiac failure, second or third-degree AV block (without pacemaker), sick sinus syndrome, and severe bradycardia. Use with caution in patients with bronchospastic disease, diabetes (may mask hypoglycemia symptoms), peripheral vascular disease, and pheochromocytoma.

Drug Interactions

Calcium channel blockers (verapamil, diltiazem) may potentiate bradycardia and AV block when combined with bisoprolol. Concomitant use with clonidine may cause rebound hypertension if clonidine is withdrawn first. NSAIDs may reduce the antihypertensive effect. Digitalis glycosides may cause additive bradycardia. MAO inhibitors and catecholamine-depleting drugs (reserpine) may have additive effects. Beta-agonists may have their effects antagonized by bisoprolol.

Special Populations

Bisoprolol should be used during pregnancy only if the potential benefit justifies the potential risk; beta-blockers may cause fetal bradycardia. It is unknown whether bisoprolol is excreted in human breast milk; caution is advised during breastfeeding. Safety and efficacy have not been established in pediatric patients. Elderly patients may require lower initial doses. Dose adjustment is required for both hepatic and renal impairment. Patients with diabetes should be monitored carefully as beta-blockers may mask hypoglycemia symptoms.